Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom 
News
On this page find all the latest news, events and activities that involves Dr. Falk Pharma.
Strategic Partnership with Allianthera (Suzhou) Biopharmaceuticals
for Novel AhR Agonist Development for the Treatment of Moderate to Severe Ulcerative Colitis
Today is World Liver Day!
Did you know that our first product back in 1960 was a therapeutic drug for the liver?
Dr. Falk Pharma acquires Kynos Therapeutics
...adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
Following the footsteps of our founder
Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.
Dosing of the First United States Patient
...and expansion of the Phase 2b Study of Naronapride in Gastroparesis
Corum – Place To Share
Read about yesterday's groundbreaking ceremony for the building in which we will be working in as of 2026.
FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-nonresponsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
ROSCREA, Ireland, and FREIBURG, Germany (GLOBE NEWSWIRE) [February, 7, 2024]– Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, announced today that its European Partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), has elected to advance the development of....
First patient treated in phase iib study of Naronapride in patients with gastroparesis
Dr. Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both through our own internal teams, and also in collaboration with key external partners.
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China.
Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma GmbH and Zedira announce start of the phase 2b clinical trial of ZED1227, a direct-acting and specific inhibitor of tissue transglutaminase, in patients with Celiac Disease.
Renexxion Ireland Ltd. & Dr. Falk Pharma GmbH announce a Licensing and Collaboration Agreement
Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal (“GI”) disorders, announced today that it has entered into a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH to jointly develop and commercialize Naronapride, a unique late-stage GI prokinetic, initially for gastroparesis.
TGA regulatory approval for Jorveza 0.5mg orally disintegrating tablets
Dr. Falk Pharma Australia is pleased to announce we have received TGA regulatory approval for Jorveza® 0.5mg orally disintegrating budesonide tablet - indicated "for the treatment of eosinophilic oesophagitis (EoE) in adults".
Adults with EOE market research survey
Dr. Falk Pharma would like to thank all responders to our survey on Adults with EoE.
Dr. Falk Pharma Australia is pleased to announce the 2022 Dr. Falk Pharma-GESA research grant
Dr. Falk Pharma Australia is pleased to announce the 2022 Dr. Falk Pharma-GESA research grant has been awarded to